Revance Reports Efficacy For Botulinum Toxin Type A

Published: 09-Jul-2009

Study showed that treatment with RT001 has been safe and well tolerated

Revance Therapeutics' RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, has demonstrated efficacy and safety in a US phase 2b clinical study.

RT001, Botulinum Toxin Type A Topical Gel, an investigational product, is designed to reduce crow’s feet wrinkles by temporarily relaxing the muscles around the eye.

The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo, at primary and multiple secondary endpoints.

The phase 2 study has demonstrated the efficacy of RT001 and the results are consistent with earlier phase 2 studies conducted in the US and internationally, said the company. More than 200 patients have been treated with RT001 and it has been safe and well tolerated.

Dan Browne, President and CEO of Revance, said: “We are very pleased with our progress and the data generated from our Phase 2 clinical program. It represents an important milestone for the company as we proceed to our End of Phase 2 meeting with the FDA later this year. I want to thank all the US and international Phase 2 Investigators and their clinical research teams for their efforts to achieve this milestone.”